Sundaram Finance Q3 FY26 Results – PAT at ₹402.87 Crore

Sundaram Finance announced its Q3 FY26 results, showcasing a Profit After Tax (PAT) of ₹402.87 crore. The Board has declared an interim dividend of ₹16 per share. Total revenue from operations stood at ₹1,910.97 crore. The company reported Earnings Per Share (EPS) of ₹36.26 for the quarter. These results reflect a solid financial performance for the company during the period.

Financial Performance

Sundaram Finance reported a Profit After Tax (PAT) of ₹402.87 crore for Q3 FY26, as approved at the Board Meeting held on February 2, 2026. The company’s total revenue from operations reached ₹1,910.97 crore for the quarter.

Dividend Announcement

The Board of Directors has declared an interim dividend of ₹16 per share (160%) for the financial year 2025-26, payable on or after February 25, 2026, to shareholders whose names are registered on the Record Date of February 6, 2026.

Key Financial Metrics

  • Earnings Per Share (EPS): ₹36.26
  • Total Revenue from Operations: ₹1,910.97 crore

Additional Highlights

The proceeds of Non-Convertible Debentures issued during the quarter ended December 31, 2025, have been fully utilized for the intended purpose. There was no deviation in the use of proceeds as compared to the objects of the issue.

The company reported incremental impact of changes in new Labour Codes under ‘Exceptional Items’ in the Standalone/ Consolidated interim statement of profit and loss for the current period, amounting to ₹65.98 crores and ₹66.84 crores respectively.

Consolidated Results Overview

The unaudited consolidated financial results include the Group’s share of net profit/(loss) after tax of ₹19.38 crores and ₹79.84 crores and total comprehensive income of ₹11.84 crores and ₹51.06 crores for the quarter and nine months ended December 31, 2025, respectively, in respect of the Joint Venture Company.

Asset Cover Certificate

The book value of assets provided as security with respect to Secured Listed Debt Securities (Non-Convertible Debentures) of the Company as at December 31, 2025, amounted to ₹18,049.61 Crores.

Source: BSE

Previous Article

eMudhra Board Approves Unaudited Financial Results for Quarter Ended December 31, 2025

Next Article

AstraZeneca Pharma India Receives ESG Score of 64.4 (Grade B)